首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention
【24h】

Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention

机译:通过VerifyNow P2Y12分析评估的P2Y12反应单位与血小板抑制百分比的组合可有效预测接受经皮冠状动脉介入治疗的急性冠脉综合征患者的长期临床结局

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Introduction: High on-treatment platelet reactivity is a well-known risk factor for adverse events in patients undergoing percutaneous coronary intervention (PCI). This study was to investigate the value of a novel platelet reactivity-based system, named the COP-INH (COmbination of P2Y12 reaction unit [ PRU] and percentage of platelet inhibition [% INH]), assessed by VerifyNow P2Y12 assay, for predicting the long-term ischaemic events in patients with acute coronary syndrome (ACS) undergoing PCI.
机译:简介:治疗中血小板反应性高是众所周知的发生经皮冠状动脉介入治疗(PCI)的患者发生不良事件的危险因素。这项研究旨在研究一种基于血小板反应性的新型系统COP-INH(P2Y12反应单位的结合[PRU]和血小板抑制百分比[%INH])的价值,该系统通过VerifyNow P2Y12分析评估,可预测接受PCI的急性冠脉综合征(ACS)患者的长期缺血事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号